摘要
目的:研究卡瑞利珠单抗与化疗联用对经载药微球-肝动脉化疗栓塞(D-TACE)后病情恶化肝癌患者的效果,以期为该类患者提供安全有效的治疗方案。方法:选取2020年1月-2022年1月丰城市人民医院接收的94例经D-TACE后病情恶化肝癌患者。以单双数字法将其分作单抗组47例及化疗组47例。化疗组开展单纯化疗,单抗组则在化疗的基础上增用卡瑞利珠单抗治疗。分析两组临床疗效、肝功能、血清肿瘤标志物水平及不良反应。结果:在疾病控制率(DCR)方面对比,单抗组高于化疗组(78.72%vs. 57.45%)(P<0.05)。治疗后在丙氨酸氨基转移酶(ALT)、天冬氨酸氨基转移酶(AST)、总胆红素(TBIL)水平方面对比,单抗组均低于化疗组(P<0.05)。治疗后在甲胎蛋白(AFP)、α-L-岩藻糖苷酶(AFU)、癌胚抗原(CEA)水平方面对比,单抗组均低于化疗组(P<0.05)。两组不良反应发生率比较,差异均无统计学意义(P>0.05)。结论:卡瑞利珠单抗联合化疗可提高D-TACE后进展的肝癌患者临床疗效,具有一定安全性,应用价值良好。
Objective:To study the effect of Carrelizumab combined with chemotherapy on liver cancer patients with worsening disease after drug-loaded microspheres-transcatheter arterial chemoembolization(D-TACE),so as to provide a safe and effective treatment plan for these patients.Method:A total of 94 patients with liver cancer whose condition worsened after D-TACE in Fengcheng People's Hospital from January 2020 to January 2022 were selected,they were divided into monoclonal antibody group(47 cases)and chemotherapy group(47 cases)by single and even number method.The chemotherapy group was treated with chemotherapy alone,and the monoclonal antibody group was treated with Carrelizumab on the basis of chemotherapy.The clinical efficacy,liver function and serum tumor markers and adverse reactions between the two groups were compared.Result:The disease control rate(DCR)in the monoclonal antibody group was higher than that in the chemotherapy group(78.72%vs.57.45%)(P<0.05).Alanine aminotransferase(ALT),aspartate aminotransferase(AST)and total bilirubin(TBIL)levels after treatment were compared,those in the monoclonal antibody group were lower than those in the chemotherapy group(P<0.05).Alpha fetal protein(AFP),α-L-fucosidase(AFU),and carcino-embryonic antigen(CEA)levels after treatment were compared,those in the monoclonal antibody group were lower than those in the chemotherapy group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Carrelizumab combined with chemotherapy can improve the clinical efficacy of patients with advanced liver cancer after D-TACE,with certain safety and good application value.
作者
徐秋平
XU Qiuping(Fengcheng People's Hospital,Jiangxi Province,Fengcheng 331100,China)
出处
《中国医学创新》
CAS
2023年第12期43-46,共4页
Medical Innovation of China
关键词
肝癌
载药微球-肝动脉化疗栓塞
卡瑞利珠单抗
Liver cancer
Drug-loaded microspheres-transcatheter arterial chemoembolization
Carrelizumab
